Who is sponsoring NCT04899414?

NCT04899414 is sponsored by Peking University.

What condition does NCT04899414 study?

NCT04899414 studies NK/T Cell Lymphoma.

Is NCT04899414 still recruiting?

NCT04899414 is currently status unknown. Last updated 24 May 2021.

Last reviewed 2021-05-24 · How we verify

NCT04899414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Status unknown Phase 2 Last updated 24 May 2021

What this trial tests

Phase 2 trial testing Dexamethasone, azacytidine, Pegaspargase, Tislelizumab in NK/T Cell Lymphoma in 50 participants. Status unknown.

Timeline

18 May 2021

Primary endpoint
18 May 2023

18 October 2023

Quick facts

Lead sponsor	Peking University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	18 May 2021
Primary completion	18 May 2023
Estimated completion	18 October 2023
Sites	3 locations across China

Drugs / interventions tested

Dexamethasone, azacytidine, Pegaspargase, Tislelizumab — full drug profile →

Conditions studied

NK/T Cell Lymphoma — all drugs for NK/T Cell Lymphoma →

Sponsor

Peking University

Who can join

Adults 18 to 70, any sex, with NK/T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed advanced stage ENKTL , non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T cell lymphoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells.
Tang Y, Cui G, Liu H, Han Y, et al · · 2024 · cited 28× · PMID 38715348 · DOI 10.1002/cac2.12546
Treatment of extranodal NK/T-cell lymphoma: From past to future.
Yan Z, Yao S, Wang Z, Zhou W, et al · · 2023 · cited 22× · PMID 36825002 · DOI 10.3389/fimmu.2023.1088685
Treatment Advances in EBV Related Lymphoproliferative Diseases.
Lv K, Yin T, Yu M, Chen Z, et al · · 2022 · cited 14× · PMID 35515118 · DOI 10.3389/fonc.2022.838817
Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L, Chen N, Dai L, Peng X. · · 2023 · cited 12× · PMID 38026157 · DOI 10.1016/j.isci.2023.108192
The Status and Prospects of Epigenetics in the Treatment of Lymphoma.
Liu J, Li JN, Wu H, Liu P. · · 2022 · cited 10× · PMID 35463343 · DOI 10.3389/fonc.2022.874645
Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies.
Zhang Q, Wang X. · · 2026 · PMID 42122154 · DOI 10.3390/cancers18091358

Verify or expand the search:

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04899414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 24 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04899414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing